ReviewHepatology international2022
SARS-CoV-2 infection and liver involvement.
Review in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 46 citations in OpenAlex.
- Integrative transcriptomic and single-cell analysis reveals a convergent cholangiocyte-associated host inflammatory program in biliary atresia and SARS-CoV-2-associated hepatobiliary injury.Frontiers in immunology · 2026Article
- Advances in plant-derived vesicle like nanoparticles-based therapies for inflammatory diseases.Asian journal of pharmaceutical sciences · 2025Review
- Hepatitis B associated with severe COVID-19: a nationwide cohort study in Sweden.Virology journal · 2025Article
- Angiotensin-converting enzyme 2 and hepatic SARS-CoV-2 infection: Regulation, association, and therapeutic implications.World journal of gastroenterology · 2025Article
- Ferroptosis and mitochondrial ROS are central to SARS-CoV-2-induced hepatocyte death.Frontiers in cellular and infection microbiology · 2025Article
- Observational
- Article
- Impact of prior SARS-CoV-2 infection on postoperative recovery in patients with hepatocellular carcinoma resection.BMC gastroenterology · 2024Article
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- Molecular mechanisms underlying SARS-CoV-2 hepatotropism and liver damage.World journal of hepatology · 2024Article
- New Insights into the Effects of SARS-CoV-2 on Metabolic Organs: A Narrative Review of COVID-19 Induced Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- COVID-19 + Cirrhosis = Excess Hospital Confinement, Excess Casualties.Digestive diseases and sciences · 2023Article
- Fuel to the fire: The impact of COVID-19 on alcohol-associated hepatitis.Alcohol, clinical & experimental research · 2023Article
- Investigating Acute Hepatitis after SARS-CoV-2 Vaccination or Infection: A Genetic Case Series.Biomedicines · 2023Article
- Identification of potential biomarkers to predict organ morbidity in COVID-19: A repository based proteomics perspective.Biochemistry and biophysics reports · 2023Article
- SARS-CoV-2 Gut-Targeted Epitopes: Sequence Similarity and Cross-Reactivity Join Together for Molecular Mimicry.Biomedicines · 2023Article
- An Updated Systematic Review and Meta-Analysis of the Association between the De Ritis Ratio and Disease Severity and Mortality in Patients with COVID-19.Life (Basel, Switzerland) · 2023Review
- Causal associations between chronic hepatitis B and COVID-19 in East Asian populations.Virology journal · 2023Article
- Unraveling the Molecular and Cellular Pathogenesis of COVID-19-Associated Liver Injury.Viruses · 2023Review
- Vaccination in liver diseases and liver Transplantation: Recommendations, implications and opportunities in the post-covid era.JHEP reports : innovation in hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
The COVID-19 pandemic is the largest public health challenge in living memory. Patients with underlying liver disease have been disproportionately affected, experiencing high morbidity and mortality. In addition, elevated liver enzymes appear to be a risk factor for disease progression, even in the absence of underlying liver disease. Nevertheless, the mechanism of liver injury in SARS-CoV-2 infection remains largely unknown. This review aims to provide an overview of the mechanisms by which SARS-CoV-2 induces liver injury, and the impact of COVID-19 on cirrhosis, alcohol-related liver disease, autoimmune liver disease, non-alcoholic fatty liver disease, hepatitis B and C virus infection, liver-transplant recipients and patients with hepatocellular carcinoma. Finally, emerging data on vaccination in liver diseases is discussed, to help inform public health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.